Synthetic Biology
PD-L1 Test Comparison Finds Varying Ability to ID Bladder Cancer Patients Who Benefit From Tecentriq
A post hoc analysis suggests that patients who are PD-L1 high by Roche's SP142 test are more likely to live longer with Tecentriq than those deemed high expressers by Agilent's 22C3 test.
Twist Bioscience, Neogene Therapeutics Partner to Develop Personalized CAR T Cells, TCR Therapies
The companies will combine Neogene's expertise in targeting tumor neoantigens with Twist's DNA synthesis platform and product lines.